FEMASYS INC FEMY
We are a leading biomedical innovator, addressing significant unmet needs in women's health worldwide, with a broad patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products. The Company is a U.S. manufacturer that has received global regulatory approvals for its product portfolio, which is currently being commercialized in the U.S. and key international markets. FemaSeed® Intratubal Insemination, a groundbreaking first-step infertility treatment delivering sperm directly to the site of conception, is U.S. FDA-cleared and approved in Europe, United Kingdom (UK), Canada, Israel, Australia and New Zealand. A peer-reviewed publication of positive data from its pivotal clinical trial of FemaSeed demonstrated effectiveness and safety with high satisfaction from both patients and practitioners. FemSperm®, which includes setup, preparation and analysis kits designed to expand our infertility portfolio and, for the first time, enables gynecologists to perform in-office sperm preparation and analysis for use with FemaSeed. FemVue®, a companion diagnostic for fallopian tube assessment via ultrasound, is U.S. FDA-cleared and approved in Europe, UK, Canada, Japan, Israel, Australia and New Zealand. FemVue Controlled is US FDA-cleared diagnostic device and is the next-generation design integrating features of FemVue and FemChec® technologies into a single platform, enabling multiple clinical uses within one solution, including confirmation of tubal patency prior to use with FemaSeed. FemCerv®, an endocervical tissue sampler for cervical cancer diagnosis, is U.S. FDA-cleared and approved in Europe, UK, Canada, Israel and New Zealand.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $2.3M | $1.6M | $1.1M | $1.2M | $1.2M | $1.0M | — |
| Cost of revenue | $872.4K | $544.9K | $380.1K | $441.9K | $370.4K | $306.5K | — |
| Gross profit | $1.4M | $1.1M | $691.9K | $764.3K | $809.3K | $731.4K | — |
| R&D | $7.6M | $8.2M | $7.2M | $5.8M | $4.1M | $4.1M | — |
| SG&A | $6.6M | $6.3M | $6.9M | $5.4M | $4.3M | $2.5M | — |
| Total operating expenses | $19.0M | $18.9M | $15.2M | $12.4M | $9.1M | $7.7M | — |
| Operating income | -$17.6M | -$17.8M | -$14.5M | -$11.6M | -$8.3M | -$6.9M | — |
| Interest expense | $1.9M | $1.6M | $165.4K | $13.5K | $19.2K | $12.6K | — |
| Pre-tax income | -$18.6M | -$18.8M | -$14.2M | -$11.4M | -$7.5M | -$6.9M | — |
| Income tax | $1.3K | $9.6K | $4.3K | $6.3K | $4.0K | $1.8K | — |
| Net income | -$18.6M | -$18.8M | -$14.2M | -$11.4M | -$7.5M | -$6.9M | — |
| EPS, basic | -0.47 | -0.85 | -0.93 | -0.96 | -1.12 | -7.20 | — |
| EPS, diluted | -0.47 | -0.85 | -0.93 | -0.96 | -1.12 | -7.20 | — |
| Shares, diluted (wtd. avg.) | 39.5M | 22.3M | 15.4M | 11.8M | 6.7M | 959,862 | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $9.3M | $3.5M | $21.7M | $13.0M | $24.8M | $3.3M | $6.4M |
| Receivables | $616.6K | $488.4K | $98.9K | $77.5K | $84.3K | $125.8K | — |
| Inventory | $5.7M | $3.0M | $667.1K | $436.7K | $208.3K | $131.4K | — |
| Total current assets | $16.5M | $8.0M | $23.2M | $14.1M | $25.6M | $3.9M | — |
| Property, plant and equipment | $1.9M | $1.6M | $1.1M | $1.5M | $1.6M | $1.8M | — |
| Other intangibles | $134.9K | $65.9K | $0 | $3.3K | $25.1K | $65.1K | — |
| Total assets | $20.7M | $12.4M | $27.8M | $16.9M | $28.6M | $7.6M | — |
| Accounts payable | $1.8M | $1.4M | $1.1M | $510.8K | $445.5K | $674.3K | — |
| Total current liabilities | $3.6M | $8.6M | $3.1M | $1.5M | $1.7M | $2.9M | — |
| Total liabilities | $14.9M | $10.1M | $9.4M | $1.7M | $2.2M | $4.1M | — |
| Retained earnings | -$145.8M | -$127.2M | -$108.4M | -$94.1M | -$82.7M | -$75.2M | — |
| Total equity | $5.9M | $2.3M | $18.4M | $15.2M | $26.3M | -$51.8M | -$45.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.7M | -$19.4M | -$11.3M | -$10.7M | -$7.9M | -$4.9M | — |
| Depreciation and amortisation | $295.9K | $277.2K | $480.2K | $539.4K | $551.1K | $560.8K | — |
| Stock-based compensation | $790.1K | $444.1K | $675.7K | $224.9K | $193.4K | $318.6K | — |
| Capital expenditure | $525.0K | $761.7K | $143.9K | $407.5K | $306.9K | $8.4K | — |
| Investing cash flow | -$630.1K | -$847.8K | -$143.9K | -$407.5K | -$306.9K | $968.3K | — |
| Financing cash flow | $25.1M | $2.0M | $20.2M | -$681.6K | $29.7M | $871.6K | — |
| Buybacks | — | $60.8K | $230.0K | $0 | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-012375.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $1.0M | $1.2M | $1.2M | $1.1M | $1.6M | $2.3M |
| Gross profit | — | $731.4K | $809.3K | $764.3K | $691.9K | $1.1M | $1.4M |
| Net income | — | -$6.9M | -$7.5M | -$11.4M | -$14.2M | -$18.8M | -$18.6M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
- Shareholder vote Item 5.07
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $117.81B | 36.6x | 11.2% |
| MMM | 3M CO | $89.46B | 28.9x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $66.22B | 23.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $54.18B | 34.2x | 8.2% |
| RMD | RESMED INC | $36.48B | 24.2x | 9.9% |
| DXCM | DEXCOM INC | $29.41B | 37.3x | 15.6% |
| MDLN | Medline Inc. | $29.20B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $27.60B | 57.8x | 6.3% |